Loading
Led the ibrutinib and brexucabtagene autoleucel trials that transformed mantle cell lymphoma treatment.
Michael Wang was principal investigator of the pivotal trial of ibrutinib in relapsed mantle cell lymphoma, the first BTK inhibitor approval in the disease, and of ZUMA-2, which established brexucabtagene autoleucel CAR-T therapy for relapsed MCL. He led the chemotherapy-free ibrutinib-rituximab WINDOW trials and the SYMPATICO trial of ibrutinib plus venetoclax. He directs the mantle cell lymphoma programme at MD Anderson.
A second randomised confirmation that adding a Bruton tyrosine kinase inhibitor to first-line bendamustine-rituximab delays progression in older patients with mantle cell lymphoma, with a toxicity profile that did not improve as much as the drug's selectivity promised.
Twenty-eight extra months of progression-free survival, with no survival gain and a high rate of severe adverse events in both arms. It set up the two trials that followed: ECHO, which substituted a more selective inhibitor, and ENRICH, which removed the chemotherapy.
ZUMA-2 gave patients with BTK-inhibitor-refractory mantle cell lymphoma, who previously had a median survival under a year, a therapy with durable remissions in a substantial fraction. Brexu-cel is now standard after BTK inhibitor failure and CAR-T is being tested earlier in the disease. Neurotoxicity rates are higher than in other lymphoma CAR-T trials.
Shares Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma, Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma, SHINE, Mantle cell lymphoma and the tags lymphoma, mantle-cell.
Shares MD Anderson Cancer Center, CD19, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, CAR-T cell therapy and the tags lymphoma, car-t.
Shares CD19, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, CAR-T cell therapy and the tags lymphoma, car-t.
Shares MD Anderson Cancer Center, CD19, CAR-T cell therapy and the tags lymphoma, car-t.
Shares Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma, Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma, SHINE, Mantle cell lymphoma.
Shares Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tags lymphoma, car-t.
Shares ZUMA-2, ZUMA-2: brexu-cel CAR-T for mantle cell lymphoma that has failed BTK inhibitors, CD19, Mantle cell lymphoma.
Shares BCL-2, Venetoclax, Mantle cell lymphoma and the tag lymphoma.